{"schema_version":"1","generated_at":"2026-11-15T02:57:49.347Z","data_as_of":"2026-11-08","url":"https://www.findmykol.com/kol/riyaz-shah","json_url":"https://www.findmykol.com/kol/riyaz-shah/profile.json","record_kind":"full","profile_kind":"research","person":{"slug":"riyaz-shah","name":"Riyaz Shah","credential":"MBBS, PhD","title":"Consultant Medical Oncologist","specialty":"Medicine","therapeutic_area":"Lung","therapeutic_areas":["Lung","Oncology"],"institution":"Maidstone and Tunbridge Wells NHS Trust","institution_url":"https://www.findmykol.com/institution/maidstone-and-tunbridge-wells-nhs-trust","register":{"country":"GB"}},"identifiers":{"orcid":"0000-0003-3374-077X","openalex":"A5091450277"},"summary":"Riyaz Shah is Consultant Medical Oncologist at Maidstone and Tunbridge Wells NHS Trust. OpenAlex indexes 89 publications with 8,920 citations (h-index 24); ClinicalTrials.gov lists 3 registered studies with this person as an investigator.","overview":{"text":"Riyaz Shah is Consultant Medical Oncologist at Maidstone and Tunbridge Wells NHS Trust. The public record shows 89 publications with 8,920 citations (h-index 24), centered on Lung Cancer Treatments and Mutations, Lung Cancer Diagnosis and Treatment, HER2/EGFR in Cancer Research. It also documents an investigator role on 3 registered clinical trials.","bullets":["Most recent indexed publication: 2021 · Drugs - real world outcomes","Top research focus: Lung Cancer Treatments and Mutations","3 registered trials on ClinicalTrials.gov"],"generated_at":"2026-11-14"},"focus":{"indications":[{"label":"Mesothelioma","therapeutic_area":"Oncology","trials":2,"topics":0,"strength":6},{"label":"Lung Cancer (NSCLC/SCLC)","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":4},{"label":"Lymphoma","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Mesothelioma, Malignant","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Small Cell Lung Carcinoma","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Bladder / Urothelial Cancer","therapeutic_area":"Oncology","trials":0,"topics":0,"strength":1},{"label":"Breast Cancer","therapeutic_area":"Oncology","trials":0,"topics":0,"strength":1},{"label":"Colorectal Cancer","therapeutic_area":"Oncology","trials":0,"topics":0,"strength":1},{"label":"Gastroesophageal Cancer","therapeutic_area":"Oncology","trials":0,"topics":0,"strength":1},{"label":"Melanoma","therapeutic_area":"Oncology","trials":0,"topics":0,"strength":1},{"label":"Ovarian / Gynecologic Cancer","therapeutic_area":"Oncology","trials":0,"topics":0,"strength":1},{"label":"Pancreatic Cancer","therapeutic_area":"Oncology","trials":0,"topics":0,"strength":1},{"label":"Prostate Cancer","therapeutic_area":"Oncology","trials":0,"topics":0,"strength":1},{"label":"Kidney Cancer / RCC","therapeutic_area":"Oncology","trials":0,"topics":0,"strength":1}],"research_topics":["Lung Cancer Treatments and Mutations","Lung Cancer Diagnosis and Treatment","HER2/EGFR in Cancer Research","Lung Cancer Research Studies","Cancer Immunotherapy and Biomarkers"],"drugs_studied":{"total":2,"shown":2,"withheld":0,"rows":[{"name":"Alectinib","trials":1,"payments":0,"publications":0,"mentions":1},{"name":"Neladalkib","trials":1,"payments":0,"publications":0,"mentions":1}]},"works_with":{"total":3,"shown":3,"withheld":0,"rows":[{"name":"Nuvalent Inc.","trials":1,"payments":0,"mentions":1},{"name":"Royal Brompton & Harefield NHS Foundation Trust","trials":1,"payments":0,"mentions":1},{"name":"University College, London","trials":1,"payments":0,"mentions":1}]}},"scholarship":{"works_count":89,"cited_by_count":8920,"h_index":24,"i10_index":36,"pubmed_count":1,"latest_activity_year":2021,"source":"works"},"trials":{"count":3,"shown":3,"withheld":0,"matched_by":"identity-adjudicated record","rows":[{"nct":"NCT06765109","title":"Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC","phase":"PHASE3","status":"RECRUITING","role":"Investigator","sponsor":"Nuvalent Inc.","source_url":"https://clinicaltrials.gov/study/NCT06765109","trial_url":"https://www.findmykol.com/trial/NCT06765109"},{"nct":"NCT05655078","title":"Hemithoracic Irradiation With Proton Therapy in Malignant Pleural Mesothelioma","phase":"NA","status":"RECRUITING","role":"Investigator","sponsor":"University College, London","source_url":"https://clinicaltrials.gov/study/NCT05655078","trial_url":"https://www.findmykol.com/trial/NCT05655078"},{"nct":"NCT02040272","title":"Mesothelioma and Radical Surgery 2","phase":"NA","status":"UNKNOWN","role":"Investigator","sponsor":"Royal Brompton & Harefield NHS Foundation Trust","source_url":"https://clinicaltrials.gov/study/NCT02040272","trial_url":"https://www.findmykol.com/trial/NCT02040272"}],"source":"trials"},"payments":{"note":"Not attributed. This person has no U.S. clinical registration (NPI) on file, so industry payments cannot be reliably tied to them."},"funding":{"award_count":0,"rows_total":0,"shown":0,"withheld":0,"rows":[],"source":"grants"},"congress":{"count":18,"years":{"first":2005,"last":2026},"societies":["AACR","ASCO","ESMO","IASLC"],"shown":3,"withheld":15,"rows":[{"title":"Abstract CT139: Germline HFE mutations predict for durable response to arginine depletion with pegargiminase-based chemotherapy in pleural mesothelioma","society":"AACR","meeting":"AACR Annual Meeting","year":2026,"role":"co_author","presentation_type":"unknown","contribution_type":"abstract","doi":"https://doi.org/10.1158/1538-7445.am2026-ct139","source_url":"https://doi.org/10.1158/1538-7445.am2026-ct139","status":"verified"},{"title":"Abstract 7147: Ultra-high throughput single-nuclei RNAs sequencing of malignant pleural mesothelioma samples in the BEAT-MESO clinical trial","society":"AACR","meeting":"AACR Annual Meeting","year":2025,"role":"co_author","presentation_type":"unknown","contribution_type":"abstract","doi":"https://doi.org/10.1158/1538-7445.am2025-7147","source_url":"https://doi.org/10.1158/1538-7445.am2025-7147","status":"verified"},{"title":"2062eP Efficacy of second-line carboplatin plus pemetrexed after osimertinib in EGFR-mutant advanced NSCLC patients: An international real-world analysis","society":"ESMO","meeting":"ESMO Congress","year":2025,"role":"co_author","presentation_type":"unknown","contribution_type":"abstract","doi":"https://doi.org/10.1016/j.annonc.2025.08.2683","source_url":"https://doi.org/10.1016/j.annonc.2025.08.2683","status":"verified"}],"source":"congress"},"publications":{"total":1,"shown":1,"withheld":0,"matched_by":"ORCID record, linked to PubMed","recent":[{"title":"European and US Real-World Treatment Patterns in Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Retrospective Medical Record Review.","year":2021,"journal":"Drugs - real world outcomes","types":["Journal Article"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/34533784/","status":"verified"}],"source":"publications"},"recognition":{"education":{"total":3,"shown":3,"rows":[{"value":"PhD, Imperial College/Hammersmith Hospital (1998-2001)","source_url":"https://www.mtw.nhs.uk/consultants/?consultant=16680&letter=S","status":"verified","collected_at":"2026-11-08"},{"value":"Membership of the Royal College of Physicians of London (MRCP), 1997","source_url":"https://www.mtw.nhs.uk/consultants/?consultant=16680&letter=S","status":"verified","collected_at":"2026-11-08"},{"value":"MBBS, qualified from Guy's and St Thomas' Hospitals, 1994","source_url":"https://www.mtw.nhs.uk/consultants/?consultant=16680&letter=S","status":"provisional","collected_at":"2026-11-08"}]},"roles":{"total":2,"shown":2,"rows":[{"value":"Steering committee member, British Thoracic Oncology Group","source_url":"https://www.mtw.nhs.uk/consultants/?consultant=16680&letter=S","status":"verified","collected_at":"2026-11-08"},{"value":"Clinical advisor, EGFR UK and ALK+UK","source_url":"https://www.mtw.nhs.uk/consultants/?consultant=16680&letter=S","status":"verified","collected_at":"2026-11-08"}]},"awards":{"total":1,"shown":1,"rows":[{"value":"ASCO Foundation Merit Award (2005)","source_url":"https://genesiscare.com/uk/our-doctors/riyaz-shah","status":"provisional","collected_at":"2026-11-08"}]},"secondary_affiliations":{"total":1,"shown":1,"rows":[{"value":"GenesisCare (private practice), Maidstone and London Cromwell Hospital","source_url":"https://genesiscare.com/uk/our-doctors/riyaz-shah","status":"provisional","collected_at":"2026-11-08"}]}},"similar":[{"name":"Rajesh Gupta","slug":"rajesh-gupta-gb","institution":"Maidstone and Tunbridge Wells NHS Trust","url":"https://www.findmykol.com/kol/rajesh-gupta-gb","json_url":"https://www.findmykol.com/kol/rajesh-gupta-gb/profile.json"},{"name":"Tamzin Cuming","slug":"tamzin-cuming","institution":"Maidstone and Tunbridge Wells NHS Trust","url":"https://www.findmykol.com/kol/tamzin-cuming","json_url":"https://www.findmykol.com/kol/tamzin-cuming/profile.json"},{"name":"Mohamed Elalfy","slug":"mohamed-elalfy","institution":"Maidstone and Tunbridge Wells NHS Trust","url":"https://www.findmykol.com/kol/mohamed-elalfy","json_url":"https://www.findmykol.com/kol/mohamed-elalfy/profile.json"},{"name":"David J. Gee","slug":"david-gee","institution":"Maidstone and Tunbridge Wells NHS Trust","url":"https://www.findmykol.com/kol/david-gee","json_url":"https://www.findmykol.com/kol/david-gee/profile.json"},{"name":"Marc Ladanyi","slug":"marc-ladanyi","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Anatomic Pathology","url":"https://www.findmykol.com/kol/marc-ladanyi","json_url":"https://www.findmykol.com/kol/marc-ladanyi/profile.json"},{"name":"Ignacio Wistuba","slug":"ignacio-wistuba","institution":"Moffitt Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/ignacio-wistuba","json_url":"https://www.findmykol.com/kol/ignacio-wistuba/profile.json"},{"name":"Pasi Janne","slug":"pasi-janne","institution":"Dana-Farber Cancer Institute","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/pasi-janne","json_url":"https://www.findmykol.com/kol/pasi-janne/profile.json"},{"name":"John Minna","slug":"john-minna","institution":"University of Texas Southwestern Medical Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/john-minna","json_url":"https://www.findmykol.com/kol/john-minna/profile.json"}],"coverage":{"note":"An identity-adjudicated profile: every section above was checked. Where a section states a count of zero, the public record was searched and nothing was found."},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"congress":15}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts","collected_at":"2026-11-08"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies","collected_at":"2026-11-08"},"grants":{"name":"NIH RePORTER","url":"https://reporter.nih.gov","provides":"Federally funded research awards, by fiscal year"},"congress":{"name":"OpenAlex","url":"https://openalex.org","provides":"DOI-verified congress abstracts across AACR, ASCO, ASH, ASTRO, ESMO","disclaimer":"Congress abstracts are published as DOI-bearing journal supplements and attributed via the same ORCID-disambiguated authorship as publications.","collected_at":"2026-11-08"},"publications":{"name":"PubMed (NLM)","url":"https://pubmed.ncbi.nlm.nih.gov","provides":"Peer-reviewed publications, linked to the PubMed record","collected_at":"2026-11-08"}},"methodology_url":"https://www.findmykol.com/about#methodology"}